Introduction
This analysis examines the current position and future outlook for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
Understand the driving force behind King's 34.8% increase in revenues in 2003
Benchmark King's performance against key rivals in the ethical pharmaceutical sector
Evaluate the success of King's "growth by acquisition" strategy
(0 items)
